Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer – New Scientific Evidences or Another Example of “Pseudo-Evidence” Medicine?
The quality of the database analysis that led to the conclusion that angiotensin converting enzyme inhibitors contribute to the development of lung cancer is analyzed. The author notes that the analysis of the potential risk from taking these drugs is possible only if it is related to the proven pos...
Saved in:
Main Author: | S. Yu. Martsevich |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2019-01-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/1803 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL INFARCTION. WHAT DO EVIDENCE-BASED MEDICINE DATA SPEAK FOR?
by: S. Yu. Martsevich
Published: (2016-01-01) -
ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01) -
Experimental evidence for the topical use of angiotensin-converting enzyme inhibitors in eye drops for eye ischemia treatment
by: N. B. Chesnokova, et al.
Published: (2022-09-01) -
Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
by: O. M. Drapkina, et al.
Published: (2020-07-01) -
THE CAPABILITIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CLINICAL PRACTICE: FOCUS ON VASOPROTECTION
by: D. B. Nebieridze, et al.
Published: (2015-12-01)